Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 05030, Republic of Korea.
Department of Nuclear Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 05030, Republic of Korea.
Medicina (Kaunas). 2023 Jan 3;59(1):105. doi: 10.3390/medicina59010105.
: Although laparoscopic cholecystectomy is the preferred treatment method in patients who experience typical biliary pain with or without gallstones, medical treatment has not been extensively studied. Rowachol is a potent choleretic agent, comprising six cyclic monoterpenes. This study aimed to investigate the clinical improvement and changes in gallbladder ejection fraction (GBEF) by Rowachol treatment in patients with typical biliary pain. : We retrospectively reviewed 138 patients with typical biliary pain who underwent cholescintigraphy from July 2016 to April 2022. We included patients who received Rowachol for more than 2 months and underwent follow-up GBEF measurements. Finally, we analyzed pre- and post-treatment symptoms and GBEF. GBEF was calculated using the fatty meal-stimulated cholescintigraphy. : This retrospective observational study included 31 patients; their median age was 46.0 (range, 26.0-72.7) years, and 22 (71.0%) were female. Overall, 9 (29.0%) patients had gallbladder stones or sludges (maximum size: 2 mm) on initial transabdominal ultrasonography. During a median follow-up of 23.3 months, the symptoms of 21 (67.7%) patients were resolved after a median Rowachol treatment of 10.0 months. The mean GBEF was significantly improved after Rowachol treatment (initial cholescintigraphy: 42.6% ± 16.2%; follow-up cholescintigraphy: 53.0% ± 18.1%, = 0.012). In patients with a GBEF ≤35% (n = 9), Rowachol significantly increased the GBEF from 21.3% ± 8.3% to 49.1% ± 20.7% ( = 0.008). : Rowachol may have beneficial medical effects that can improve gallbladder dysfunction and treatment response.
虽然腹腔镜胆囊切除术是伴有或不伴有胆囊结石的典型胆绞痛患者的首选治疗方法，但药物治疗尚未得到广泛研究。Rowachol 是一种有效的利胆剂，由六种环状单萜组成。本研究旨在探讨 Rowachol 治疗典型胆绞痛患者的临床改善和胆囊排空分数（GBEF）的变化。
我们回顾性分析了 2016 年 7 月至 2022 年 4 月间接受闪烁扫描的 138 例有典型胆绞痛的患者。我们纳入了接受 Rowachol 治疗超过 2 个月并进行了后续 GBEF 测量的患者。最后，我们分析了治疗前后的症状和 GBEF。GBEF 是通过脂肪餐刺激闪烁扫描计算得出的。
这项回顾性观察研究共纳入 31 例患者；中位年龄为 46.0（范围 26.0-72.7）岁，22 例（71.0%）为女性。总体而言，9 例（29.0%）患者在初次腹部超声检查时发现胆囊结石或胆泥（最大直径 2mm）。在中位随访 23.3 个月期间，中位治疗 10.0 个月后，21 例（67.7%）患者的症状得到缓解。Rowachol 治疗后 GBEF 显著改善（初次闪烁扫描：42.6%±16.2%；随访闪烁扫描：53.0%±18.1%， = 0.012）。在 GBEF ≤35%的患者中（n=9），Rowachol 可使 GBEF 从 21.3%±8.3%显著增加至 49.1%±20.7%（ = 0.008）。
Rowachol 可能具有有益的药物作用，可以改善胆囊功能障碍和治疗反应。
